WY 50295

Drug Profile

WY 50295

Alternative Names: WY 50295-tromethamine

Latest Information Update: 05 Oct 2011

Price : $50

At a glance

  • Originator Wyeth
  • Class Antiallergics; Antiasthmatics; Antirheumatics
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Asthma; Rheumatic disorders

Most Recent Events

  • 01 Jul 1998 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
  • 01 Jul 1998 No-Development-Reported for Asthma in USA (Unknown route)
  • 14 Dec 1994 Investigation in Rheumatic disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top